McLaren Resources Inc
BeiGene to Present Extensive Hematology Data at EHA 2025, Showcasing BRUKINSA and Next-Generation Therapies
BeiGene will present 31 abstracts at the European Hematology Association Congress in Milan, highlighting data from its BTK inhibitor BRUKINSA and investigational pipeline assets sonrotoclax and BGB-16673.
Phase 3 ECOG-ACRIN EA4151 Trial Evaluates Necessity of Auto-HCT in Modern MCL Treatment
The phase 3 ECOG-ACRIN EA4151 trial is investigating whether autologous hematopoietic cell transplantation (auto-HCT) still benefits mantle cell lymphoma patients in the era of improved first-line therapies.
Study Reveals Superior Survival Outcomes for CLL and MCL Patients at Academic Cancer Centers
A nationwide study of over 9,700 patients demonstrates significantly better survival rates for CLL and MCL patients treated at academic centers compared to community settings.
Acalabrutinib Regimen Shows Promise in Untreated Mantle Cell Lymphoma
Acalabrutinib, umbralisib, and ublituximab (AU2) demonstrated a 100% objective response rate in patients with de novo mantle cell lymphoma (MCL).
clonoSEQ Data Show MRD Assessment Impacts Blood Cancer Treatment Decisions
Data from the ECOG-ACRIN EA4151 trial suggests auto-HCT may not benefit MCL patients in first complete remission with undetectable MRD.
FDA Grants Priority Review to Calquence for Untreated Mantle Cell Lymphoma
The FDA granted Priority Review to AstraZeneca's Calquence (acalabrutinib) for untreated mantle cell lymphoma (MCL), expediting its potential approval.
CALQUENCE Plus Chemoimmunotherapy Shows 27% Reduction in Disease Progression Risk for Untreated Mantle Cell Lymphoma
The ECHO Phase III trial demonstrated that CALQUENCE (acalabrutinib) combined with bendamustine and rituximab significantly reduced disease progression or death risk by 27% compared to standard chemoimmunotherapy in previously untreated mantle cell lymphoma patients.
Pirtobrutinib Shows High Response Rates in Relapsed CLL Patients with BTK Mutations
Pirtobrutinib demonstrated an 83% overall response rate in heavily pretreated chronic lymphocytic leukemia patients with BTK mutations, according to genomic analysis from the phase 1/2 BRUIN trial.
Bispecific CD20/CD19 CAR T-Cell Therapy Shows Promising Results in Mantle Cell Lymphoma
LV20.19 CAR, a novel bispecific CAR T-cell therapy targeting both CD19 and CD20 B-cell antigens, achieved a 100% overall response rate in patients with relapsed/refractory mantle cell lymphoma.